LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
==== Methylation ==== Methylation of rRNA upholds structural rigidity by blocking base pair stacking and surrounds the 2'-OH group to block hydrolysis. It occurs at specific parts of eukaryotic rRNA. The template for methylation consists of 10-21 nucleotides. 2'-O-methylation of the ribose sugar is one of the most common rRNA modifications. Methylation is primarily introduced by small nucleolar RNA's, referred to as snoRNPs. There are two classes of snoRNPs that target methylation sites, and they are referred to box C/D and box H/ACA. One type of methylation, 2′-O-methylation, contributes to helical stabilization.
Facelift was certified gold by the Recording Industry Association of America (RIAA) for selling 500,000 copies on September 11, 1991, becoming the first album from Seattle's grunge movement to be certified gold. The band continued to hone its audience, opening for such artists as Iggy Pop, Van Halen, Poison, and Extreme. Facelift has since been certified triple-platinum by the RIAA, for shipments of 3,000,000 copies in the US. The concert at the Moore Theatre in Seattle on December 22, 1990, was recorded and released on VHS in mid-1991, as Live Facelift. It features five live songs and three music videos. The home video has been certified gold by the RIAA for sales exceeding 50,000 copies. In early 1991, Alice in Chains landed the opening slot for the Clash of the Titans tour with Anthrax, Megadeth, and Slayer, exposing the band to a wide metal audience but receiving mainly poor reception. Alice in Chains was nominated for a Best Hard Rock Performance Grammy Award in 1992 for "Man in the Box". Following the tour, Alice in Chains entered the studio to record demos for its next album, but ended up recording five acoustic songs instead. While in the studio, drummer Sean Kinney had a dream about "making an EP called Sap". The band decided "not to mess with fate", and on February 4, 1992, Alice in Chains released their second EP, Sap. The EP was released while Nirvana's Nevermind was at the top of the Billboard 200 charts, resulting in a rising popularity of Seattle-based bands, and of the term "grunge music". Sap was certified gold within two weeks.
The great danger of our situation consists in the fact that on the one hand, this is a war whose direction and decision are in the hands of the great powers engaged in it for life or death, and at the same time, we do not have a repertoire of tangible objectives to mark and govern our path... no pending territorial dispute... an invasion... we do not even have a common border with enemy countries.... We run the risk of entering into a rather ideological war of solidarity with the United States of America.... Under these conditions we are seriously exposed to a deadly annulment of our national personality. Nonetheless, labour leader and head of the Mexican left Vicente Lombardo Toledano supported the allied cause in the tribunes and advised the president not to take refuge in prudence because the time had come for the country to honor its traditions. The idea of national unity prevailed, and 1942 was declared the "Year of Effort", with the multiplication in all the media of allusive messages always accompanied by a Mexican flag such as:
Sources: en.wikipedia.org
=== Demonstration against the Civitas movement === On November 18, 2012, Stern participated in protests by Femen France against a Civitas demonstration opposing same-sex marriage and suffered violence from members of the political party. Accused of public insult towards fundamentalist Catholics, she was acquitted on November 19, 2024. She was also accused, along with six other Femen members, of having used fire extinguishers as an "improvised weapon" with six other Femen members. She then obtained a first dismissal on November 19, 2024. She was again acquitted of the facts on October 24, 2024. On May 29, 2013, she participated in the first Femen demonstration in an Arab country with two other activists in Tunisia, in support of Amina Sboui. They were arrested and detained for a month in a Manouba prison. On June 12, 2013, they were sentenced to 4 months and one day in prison for "violating public morality and decency".
History of sonochemistry – history of the study of the effect of sonic waves and wave properties on chemical systems. History of stereochemistry – history of the study of the relative spatial arrangement of atoms within molecules. History of supramolecular chemistry – history of the area of chemistry beyond the molecules and focuses on the chemical systems made up of a discrete number of assembled molecular subunits or components. History of thermochemistry – history of the study of energy and heat associated with chemical reactions and/or physical transformations. History of phytochemistry – history of the study of phytochemicals. History of polymer chemistry – history of the multidisciplinary science that deals with the chemical synthesis and chemical properties of polymers or macromolecules. History of solid-state chemistry – history of the study of the synthesis, structure, and properties of solid phase materials, particularly, but not necessarily exclusively of, non-molecular solids History of multidisciplinary fields involving chemistry: History of chemical biology – history of the scientific discipline spanning the fields of chemistry and biology that involves the application of chemical techniques and tools, often compounds produced through synthetic chemistry, to the study and manipulation of biological systems. History of chemical oceanography – history of the study of the behavior of chemical elements within the Earth's oceans.
=== Fa–Fi === Kazimierz Fajans (1887–1975), Polish-American physical chemist, who worked on radioactivity and co-discovered protactinium Michael Faraday (1791–1867), British chemist and physicist who discovered include the principles of electromagnetic induction, diamagnetism, and electrolysis Hermann von Fehling (1812–1885), German chemist who developed use of Fehling's solution for estimation of sugar John Bennett Fenn (1917–2010), 2002 Nobel Prize in Chemistry for work in mass spectrometry Enrico Fermi (1901–1954), Nuclear chemist and elementary particle physicist, Nobel Prize in Physics 1938 Louis Fieser (1899–1977), American chemist who work on blood-clotting agents including the first synthesis of vitamin K, and was the author of numerous textbooks Mary Peters Fieser (1909–1997), American chemist who worked on quinones and steroids, and was co-author of chemistry books Barbara J. Finlayson-Pitts (PhD 1973), Canadian-American chemist who works on the chemistry of the upper and lower atmosphere Emil Fischer (1852–1919), 1902 Nobel Prize in Chemistry, known for work on stereochemistry and for the lock and key mechanism of enzyme action Emily V.
Shortness of breath, particularly with exertion Chronic dry, hacking coughing Fatigue and weakness Chest discomfort, including chest pain Loss of appetite and rapid weight loss Pulmonary fibrosis is suggested by a history of progressive shortness of breath (dyspnea) with exertion. Sometimes fine inspiratory crackles can be heard at the lung bases on auscultation. A chest X-ray may not be abnormal, but high-resolution CT will often show abnormalities.
Sources: en.wikipedia.org
== Applications == In biochemistry, the process of breaking down large molecules by splitting their internal bonds is catabolism. Enzymes which catalyse bond cleavage are known as lyases, unless they operate by hydrolysis or oxidoreduction, in which case they are known as hydrolases and oxidoreductases respectively. In proteomics, cleaving agents are used in proteome analysis, where proteins are cleaved into smaller peptide fragments. Examples of cleaving agents used are cyanogen bromide, pepsin, and trypsin.
Tertomotide (GV1001, EARPALLTSRLRFIPK) is a 16-amino acid peptide based on the 616‑626 position fragment of human telomerase reverse transcriptase protein (hTERT). It was originally developed as a possible subunit vaccine for various types of cancer, as it can trigger immune attack against cancer cells which overexpress telomerase, a common mutation found in malignant tumors. However, it does not block telomerase activity in healthy tissue and has been found to produce various useful activities in its own right including antiviral, antiinflammatory and antidepressant effects, and has been trialled for numerous other medical applications including Alzheimer's disease as well as its original role in the treatment of cancer.
=== Availability === Methenamine is approved and available in the United States. Only methenamine hippurate, the twice-daily formulation, is available as a prescription drug in the United States. Of 38 countries that were surveyed in one study, methenamine was available in seven of them. In any case, methenamine was marketed as a prescription drug widely throughout the world in 2004. The topical form of methenamine for hyperhidrosis has been marketed only in certain countries, including Austria, Canada, Germany, Luxembourg, and Switzerland.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.